Renal Anemia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 117 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Renal Anemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Renal Anemia - Pipeline Review, H2 2014', provides an overview of the Renal Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Renal Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Renal Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Renal Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Renal Anemia Overview 9
Therapeutics Development 10
Pipeline Products for Renal Anemia - Overview 10
Pipeline Products for Renal Anemia - Comparative Analysis 11
Renal Anemia - Therapeutics under Development by Companies 12
Renal Anemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Renal Anemia - Products under Development by Companies 19
Renal Anemia - Companies Involved in Therapeutics Development 21
Hospira, Inc. 21
Medgenics Inc. 22
Amgen Inc. 23
GlaxoSmithKline plc 24
Daiichi Sankyo Company, Limited 25
FibroGen, Inc. 26
Japan Tobacco Inc. 27
Zydus Cadila Healthcare Limited 28
Bayer AG 29
3SBio Inc. 30
ProMetic Life Sciences Inc. 31
JCR Pharmaceuticals Co., Ltd. 32
CCM Duopharma Biotech Bhd. 33
Panacea Biotec Limited 34
Affymax, Inc. 35
Myungmoon pharmaceutical Co.,Ltd. 36
Intas Pharmaceuticals Ltd. 37
Acceleron Pharma, Inc. 38
Pieris AG 39
Noxxon Pharma AG 40
Aprogen, Inc. 41
Dong-A Socio Group 42
Renal Anemia - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
peginesatide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
darbepoetin alfa - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
epoetin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
epoetin alfa - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Peg-EPO - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
roxadustat - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
sotatercept - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GSK-1278863 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
lexaptepid pegol - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
molidustat - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MDGN-201 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
PEG-EPO - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
FG-2216 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PRS-080 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
epoetin alfa - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
JTZ-951 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
epoetin alfa - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
DS-1093 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
NuPIAO - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PBI-1402 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PBI-4050 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ZP-EPO - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
darbepoetin alfa - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
darbepoetin alfa - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
darbepoetin alfa - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
darbepoetin alfa - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
MM-P01-01 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Recombinant Protein for Renal Anemia - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Renal Anemia - Recent Pipeline Updates 91
Renal Anemia - Dormant Projects 106
Renal Anemia - Discontinued Products 107
Renal Anemia - Product Development Milestones 108
Featured News & Press Releases 108
Sep 26, 2013: ProMetic's Lead Drug Candidate, PBI-4050, Enters Clinical Program 108
Sep 13, 2013: Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP for Pediatric Patients with renal anemia in Japan 108
Jul 31, 2013: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease 109
Apr 16, 2013: Amgen To Pay US $24.9m To Resolve False Claims Act Allegations 109
Jan 16, 2013: Amgen Announces Top-Line Results Of Phase III Aranesp RED-HF Trial 110
Dec 12, 2012: FibroGen And Astellas Pharma Initiates Phase III Trial Of FG-4592/ASP1517 For Treatment Of Anemia Of Chronic Kidney Disease 111
Nov 05, 2012: FibroGen Reports Data From Phase II Study Of FG-4592 Hemoglobin Correction And Maintenance In End-Stage Renal Patients 112
Oct 31, 2012: FibroGen To Present Phase II Data Of FG-4592 At American Society Of Nephrology Kidney Week 2012 113
Oct 25, 2012: Sandoz Begins Phase III Studies In US For Biosimilar Epoetin Alfa 114
Feb 13, 2012: Xenetic Commences Phase I/IIa IV Trial For ErepoXen 114
Appendix 116
Methodology 116
Coverage 116
Secondary Research 116
Primary Research 116
Expert Panel Validation 116
Contact Us 117
Disclaimer 117

List of Tables
Number of Products under Development for Renal Anemia, H2 2014 10
Number of Products under Development for Renal Anemia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Renal Anemia - Pipeline by Hospira, Inc., H2 2014 21
Renal Anemia - Pipeline by Medgenics Inc., H2 2014 22
Renal Anemia - Pipeline by Amgen Inc., H2 2014 23
Renal Anemia - Pipeline by GlaxoSmithKline plc, H2 2014 24
Renal Anemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 25
Renal Anemia - Pipeline by FibroGen, Inc., H2 2014 26
Renal Anemia - Pipeline by Japan Tobacco Inc., H2 2014 27
Renal Anemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 28
Renal Anemia - Pipeline by Bayer AG, H2 2014 29
Renal Anemia - Pipeline by 3SBio Inc., H2 2014 30
Renal Anemia - Pipeline by ProMetic Life Sciences Inc., H2 2014 31
Renal Anemia - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2014 32
Renal Anemia - Pipeline by CCM Duopharma Biotech Bhd., H2 2014 33
Renal Anemia - Pipeline by Panacea Biotec Limited, H2 2014 34
Renal Anemia - Pipeline by Affymax, Inc., H2 2014 35
Renal Anemia - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H2 2014 36
Renal Anemia - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 37
Renal Anemia - Pipeline by Acceleron Pharma, Inc., H2 2014 38
Renal Anemia - Pipeline by Pieris AG, H2 2014 39
Renal Anemia - Pipeline by Noxxon Pharma AG, H2 2014 40
Renal Anemia - Pipeline by Aprogen, Inc., H2 2014 41
Renal Anemia - Pipeline by Dong-A Socio Group, H2 2014 42
Assessment by Monotherapy Products, H2 2014 43
Number of Products by Stage and Target, H2 2014 45
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Renal Anemia Therapeutics - Recent Pipeline Updates, H2 2014 91
Renal Anemia - Dormant Projects, H2 2014 106
Renal Anemia - Discontinued Products, H2 2014 107